Literature DB >> 28914096

MicroRNAs as biomarkers for clinical studies.

Igor P Pogribny1.   

Abstract

The development of better diagnostic and prognostic non-invasive biomarkers holds an enormous potential to improve the ability to diagnose and individualize treatment of a great number of human diseases and substantially reduce health care cost. The discovery of a fundamental role of microRNAs in the disease pathogenesis and their presence and stability in biological fluids has led to extensive investigation of the role of microRNAs as potential non-invasive biomarkers for disease diagnosis and prognosis. The result of this research has suggested that alterations of microRNAs may be sensitive indicators of various pathologies; however, despite the indisputable progress in this field, the diagnostic promise of microRNAs has remained a work in progress, and circulating microRNAs have not entered the field of clinical medicine yet. Commonly reported microRNAs as disease biomarkers are largely not disease-specific and the results are often contradicting in independent studies. This review summarizes the current knowledge on the role of microRNAs as disease indicators and emphasizes the current gaps, challenges, and questions that need to be addressed in future well-designed and well-controlled studies for a successful translation of microRNA profiling into clinically meaningful tests. Impact statement This review summarizes the current knowledge on the role of circulating miRNAs as clinical diagnostic biomarkers and highlights the challenges that need to be addressed in future studies for a successful translation of circulating miRNAs into a novel diagnostic tool.

Entities:  

Keywords:  Biomarkers; MicroRNA; blood; clinical; diseases; monitoring

Mesh:

Substances:

Year:  2017        PMID: 28914096      PMCID: PMC5813862          DOI: 10.1177/1535370217731291

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  79 in total

Review 1.  MicroRNAs in Cardiovascular Disease.

Authors:  Temo Barwari; Abhishek Joshi; Manuel Mayr
Journal:  J Am Coll Cardiol       Date:  2016-12-13       Impact factor: 24.094

2.  AACR Cancer Progress Report 2016.

Authors:  Nancy E Davidson; Scott A Armstrong; Lisa M Coussens; Marcia R Cruz-Correa; Ralph J DeBerardinis; James H Doroshow; Margaret Foti; Patrick Hwu; Thomas W Kensler; Monica Morrow; Charles G Mulligan; William Pao; Elizabeth A Platz; Thomas J Smith; Cheryl L Willman
Journal:  Clin Cancer Res       Date:  2016-10-01       Impact factor: 12.531

3.  Circulating miR-210 predicts survival in critically ill patients with acute kidney injury.

Authors:  Johan M Lorenzen; Jan T Kielstein; Carsten Hafer; Shashi K Gupta; Philipp Kümpers; Robert Faulhaber-Walter; Hermann Haller; Danilo Fliser; Thomas Thum
Journal:  Clin J Am Soc Nephrol       Date:  2011-06-23       Impact factor: 8.237

4.  Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease.

Authors:  Helen M Heneghan; Nicola Miller; Ronan Kelly; John Newell; Michael J Kerin
Journal:  Oncologist       Date:  2010-06-24

5.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

6.  Circulating microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis.

Authors:  Jeanine Ward; Chitra Kanchagar; Isana Veksler-Lublinsky; Rosalind C Lee; Mitchell R McGill; Hartmut Jaeschke; Steven C Curry; Victor R Ambros
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

7.  Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma.

Authors:  Youhei Tanaka; Hidenobu Kamohara; Kouichi Kinoshita; Junji Kurashige; Takatsugu Ishimoto; Masaaki Iwatsuki; Masayuki Watanabe; Hideo Baba
Journal:  Cancer       Date:  2012-12-07       Impact factor: 6.860

8.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

9.  Absolute quantification of cell-free microRNAs in cancer patients.

Authors:  Manuela Ferracin; Laura Lupini; Irene Salamon; Elena Saccenti; Maria Vittoria Zanzi; Andrea Rocchi; Lucia Da Ros; Barbara Zagatti; Gentian Musa; Cristian Bassi; Alessandra Mangolini; Giorgio Cavallesco; Antonio Frassoldati; Stefano Volpato; Paolo Carcoforo; Alan B Hollingsworth; Massimo Negrini
Journal:  Oncotarget       Date:  2015-06-10

10.  Serum microRNA signatures as "liquid biopsies" for interrogating hepatotoxic mechanisms and liver pathogenesis in human.

Authors:  Julian Krauskopf; Theo M de Kok; Shelli J Schomaker; Mark Gosink; Deborah A Burt; Patricia Chandler; Roscoe L Warner; Kent J Johnson; Florian Caiment; Jos C Kleinjans; Jiri Aubrecht
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

View more
  26 in total

1.  Expression of microRNAs in human platelet-poor plasma: analysis of the factors affecting their expression and association with proximal genetic variants.

Authors:  Alba Rodriguez-Rius; Angel Martinez-Perez; Sonia López; Maria Sabater-Lleal; Juan Carlos Souto; José Manuel Soria
Journal:  Epigenetics       Date:  2020-06-24       Impact factor: 4.528

2.  Unique circulating microRNA associations with dysglycemia in people living with HIV and alcohol use.

Authors:  Brianna L Bourgeois; Hui-Yi Lin; Alice Y Yeh; Danielle E Levitt; Stefany D Primeaux; Tekeda F Ferguson; Patricia E Molina; Liz Simon
Journal:  Physiol Genomics       Date:  2021-12-03       Impact factor: 4.297

3.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

Review 4.  Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values.

Authors:  Kuldeep Dhama; Shyma K Latheef; Maryam Dadar; Hari Abdul Samad; Ashok Munjal; Rekha Khandia; Kumaragurubaran Karthik; Ruchi Tiwari; Mohd Iqbal Yatoo; Prakash Bhatt; Sandip Chakraborty; Karam Pal Singh; Hafiz M N Iqbal; Wanpen Chaicumpa; Sunil Kumar Joshi
Journal:  Front Mol Biosci       Date:  2019-10-18

5.  Identification of Novel miRNAs in the F8 Gene Via Bioinformatics Tools.

Authors:  Halimeh Rezaei; Majid Motovali-Bashi; Sheyda Khalilian
Journal:  Iran J Biotechnol       Date:  2021-04-01       Impact factor: 1.671

6.  MicroRNA Ratios Distinguish Melanomas from Nevi.

Authors:  Rodrigo Torres; Ursula E Lang; Miroslav Hejna; Samuel J Shelton; Nancy M Joseph; A Hunter Shain; Iwei Yeh; Maria L Wei; Michael C Oldham; Boris C Bastian; Robert L Judson-Torres
Journal:  J Invest Dermatol       Date:  2019-09-30       Impact factor: 8.551

7.  Human blood microRNA hsa-miR-21-5p induces vitellogenin in the mosquito Aedes aegypti.

Authors:  Hugo D Perdomo; Mazhar Hussain; Rhys Parry; Kayvan Etebari; Lauren M Hedges; Guangmei Zhang; Benjamin L Schulz; Sassan Asgari
Journal:  Commun Biol       Date:  2021-07-09

Review 8.  miR-223: An Effective Regulator of Immune Cell Differentiation and Inflammation.

Authors:  Peng Jiao; Xing-Ping Wang; Zhuo-Ma Luoreng; Jian Yang; Li Jia; Yun Ma; Da-Wei Wei
Journal:  Int J Biol Sci       Date:  2021-06-04       Impact factor: 6.580

9.  In Silico Integrative Approach Revealed Key MicroRNAs and Associated Target Genes in Cardiorenal Syndrome.

Authors:  Romana Ishrat; Mohd Murshad Ahmed; Safia Tazyeen; Aftab Alam; Anam Farooqui; Rafat Ali; Nikhat Imam; Naaila Tamkeen; Shahnawaz Ali; Md Zubbair Malik; Armiya Sultan
Journal:  Bioinform Biol Insights       Date:  2021-06-30

10.  Comparison of miRNA quantitation by Nanostring in serum and plasma samples.

Authors:  Catherine Foye; Irene K Yan; Waseem David; Neha Shukla; Yacob Habboush; Lori Chase; Kristen Ryland; Vivek Kesari; Tushar Patel
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.